These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36404242)

  • 21. Association between pre-treatment IQ and educational achievement after gender-affirming treatment including puberty suppression in transgender adolescents.
    Arnoldussen M; Hooijman EC; Kreukels BP; de Vries AL
    Clin Child Psychol Psychiatry; 2022 Oct; 27(4):1069-1076. PubMed ID: 35638479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bell v Tavistock: Why the Assent Model Is Most Appropriate for Decisions Regarding Puberty Suppression for Transgender and Gender Diverse Youth.
    Notini L
    J Law Med; 2021 Mar; 28(3):632-644. PubMed ID: 34369120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective comparison study of subcutaneous and intramuscular testosterone injections in transgender male adolescents.
    Baines HK; Connelly KJ
    J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1028-1036. PubMed ID: 37788646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Care for Transgender Young People.
    Krebs D; Harris RM; Steinbaum A; Pilcher S; Guss C; Kremen J; Roberts SA; Baskaran C; Carswell J; Millington K
    Horm Res Paediatr; 2022; 95(5):405-414. PubMed ID: 35272283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of leuprolide therapy in children with central precocious puberty.
    Kappy MS; Stuart T; Perelman A
    Am J Dis Child; 1988 Oct; 142(10):1061-4. PubMed ID: 3140654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic.
    Abulateefeh SR
    Drug Deliv Transl Res; 2023 Feb; 13(2):520-530. PubMed ID: 35976565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Youth and Caregiver Perspectives on Barriers to Gender-Affirming Health Care for Transgender Youth.
    Gridley SJ; Crouch JM; Evans Y; Eng W; Antoon E; Lyapustina M; Schimmel-Bristow A; Woodward J; Dundon K; Schaff R; McCarty C; Ahrens K; Breland DJ
    J Adolesc Health; 2016 Sep; 59(3):254-261. PubMed ID: 27235374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Gonadotropin-Releasing Hormone Analogue Use With Subsequent Use of Gender-Affirming Hormones Among Transgender Adolescents.
    Nos AL; Klein DA; Adirim TA; Schvey NA; Hisle-Gorman E; Susi A; Roberts CM
    JAMA Netw Open; 2022 Nov; 5(11):e2239758. PubMed ID: 36318207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review: Puberty blockers for transgender and gender diverse youth-a critical review of the literature.
    Rew L; Young CC; Monge M; Bogucka R
    Child Adolesc Ment Health; 2021 Feb; 26(1):3-14. PubMed ID: 33320999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth, growth potential, and influences on adult height in the transgender and gender-diverse population.
    Roberts SA; Carswell JM
    Andrology; 2021 Nov; 9(6):1679-1688. PubMed ID: 33969625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.
    Cukierski MJ; Johnson PA; Beck JC
    Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced growth hormone secretion prolongs puberty but does not delay the developmental increase in luteinizing hormone in the absence of gonadal negative feedback.
    Wilson ME; Chikazawa K; Fisher J; Mook D; Gould KG
    Biol Reprod; 2004 Aug; 71(2):588-97. PubMed ID: 15115727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth.
    Mejia-Otero JD; White P; Lopez X
    Transgend Health; 2021; 6(1):31-35. PubMed ID: 33614957
    [No Abstract]   [Full Text] [Related]  

  • 35. Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.
    Iwamoto SJ; Grimstad F; Irwig MS; Rothman MS
    J Gen Intern Med; 2021 May; 36(5):1380-1389. PubMed ID: 33547576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of gender-affirming treatment on bone health in transgender and gender diverse youth.
    Ciancia S; Dubois V; Cools M
    Endocr Connect; 2022 Nov; 11(11):. PubMed ID: 36048500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Hormone Concentrations in Transgender Youth Receiving Estradiol.
    Sumerwell C; Carlin K; Walsh E; Hodax JK
    Endocr Pract; 2024 Feb; 30(2):155-159. PubMed ID: 38029927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
    Cohen D; Janfaza M; Klein KO
    J Pediatr Endocrinol Metab; 2009 Jul; 22(7):629-34. PubMed ID: 19774844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists.
    Lawson ML; Cohen N
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4536-40. PubMed ID: 10599714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.